Is Mimedx Group Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: MDXG) stock is to Strong Buy MDXG stock.
Out of 2 analysts, 1 (50%) are recommending MDXG as a Strong Buy, 1 (50%) are recommending MDXG as a Buy, 0 (0%) are recommending MDXG as a Hold, 0 (0%) are recommending MDXG as a Sell, and 0 (0%) are recommending MDXG as a Strong Sell.
What is MDXG's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: MDXG) forecast ROE is N/A, which is considered weak.
What is MDXG's Price Target?
According to 2 Wall Street analysts that have issued a 1 year MDXG price target, the average MDXG price target is $11.50, with the highest MDXG stock price forecast at $12.00 and the lowest MDXG stock price forecast at $11.00.
On average, Wall Street analysts predict that Mimedx Group's share price could reach $11.50 by Aug 2, 2024. The average Mimedx Group stock price prediction forecasts a potential upside of 48.39% from the current MDXG share price of $7.75.
What is MDXG's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: MDXG) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.11%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.